DDR | Jotup

Sentra Announces Industry-First Generative AI Assistant for Cloud Data Security

Retrieved on:

Tuesday, March 5, 2024

Risk management, Generative, Communication, Synthetic media, Blog, LLM, DDR, Organization, Jagger, Policy, Integration, Privacy, Medical device

NEW YORK, March 5, 2024 /PRNewswire/ -- Sentra, a cloud-native data security platform pioneer, today announced Sentra Jagger, the industry's first Large Language Model (LLM)-assistant for cloud data security. This new capability enhances the functionality of Sentra's core Data Security Posture Management (DSPM) and Data Detection and Response (DDR) platform by enabling users to promptly address emerging threats and vulnerabilities with real-time insights, as well as extending its usability to other governance roles such as audit, compliance and privacy. This expansion advances the holistic visibility into an organization's security posture, ensuring alignment, effective communication and improved risk management.

Key Points:

NEW YORK, March 5, 2024 /PRNewswire/ -- Sentra, a cloud-native data security platform pioneer, today announced Sentra Jagger, the industry's first Large Language Model (LLM)-assistant for cloud data security.
Sentra Jagger is an AI-powered data security assistant that helps analyze and respond to security threats quickly, reducing as much as 80% of the time required to accomplish tasks, such as policy implementation and data store reporting.
By reducing the time needed to investigate and fix security threats, Sentra Jagger improves overall operational efficiency and fortifies security measures.
Security teams can use Sentra Jagger to get insights and recommendations on specific security actions through an interactive, user-friendly interface.

Ram BOP Industry Research Report 2024: A $31.58 Billion Market in 2023 - Global Industry Size, Share, Trends, Opportunities, & Forecasts 2019-2029

Retrieved on:

Friday, February 23, 2024

DUBLIN, Feb. 22, 2024 /PRNewswire/ -- The "Ram BOP Market - Global Industry Size, Share, Trends, Opportunity, & Forecast 2019-2029" report has been added to ResearchAndMarkets.com's offering.

Key Points:

DUBLIN, Feb. 22, 2024 /PRNewswire/ -- The "Ram BOP Market - Global Industry Size, Share, Trends, Opportunity, & Forecast 2019-2029" report has been added to ResearchAndMarkets.com's offering.
The global Ram BOP market is experiencing a significant boost due to the escalating demand for smartphones and electronic devices.
Technological advancements and continuous innovation in the field of memory storage technologies serve as a key driver for the global RAM BOP market.
Company Profiles: Detailed analysis of the major companies present in the Global Ram BOP Market.

IN8bio Announces Publication on Novel Gamma-Delta T Cell Therapy for Glioblastoma in Frontiers in Immunology

Retrieved on:

Wednesday, February 14, 2024

Glioblastoma, Neoplasm, PFS, Progression-free survival, Recurrence, Toxicity, Quality of life, TMZ, GBM, Cell, Safety, DDR, DRI, Patient, Brain, Survival, NKG2D, Temozolomide, DNA, Radiation, Vaccine

(NASDAQ: INAB), a leading clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies, today announced a publication in Frontiers in Immunology that reviews IN8bio’s novel approach for solid tumors, such as glioblastoma (GBM), an aggressive form of brain cancer.

Key Points:

(NASDAQ: INAB), a leading clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies, today announced a publication in Frontiers in Immunology that reviews IN8bio’s novel approach for solid tumors, such as glioblastoma (GBM), an aggressive form of brain cancer.
Cellular therapies, particularly chimeric antigen receptor T cell therapies (CAR-T), have shown promise in hematologic malignancies but have faced significant challenges when applied to solid tumors like GBM.
The INB-200 and INB-400 studies by IN8bio addresses the challenges towards targeting solid tumors by harnessing the innate immune functions of gamma-delta T cells.
IN8bio is also conducting a Phase 2 clinical trial of a genetically modified autologous gamma-delta T cell therapy (INB-400) targeting newly diagnosed GBM.

AMD Powers AI Track Inspection Solution for Japanese Bullet Train Operator JR Kyushu

Retrieved on:

Tuesday, February 13, 2024

AI, Intelligence, Aluminium, Safety, Kyushu Railway Company, Foot, SOM, Health care, DDR, AMD, JR, Kria, Heart, Robotics, Rail transport

SANTA CLARA, Calif., Feb. 13, 2024 (GLOBE NEWSWIRE) -- AMD (NASDAQ: AMD) today announced that JR Kyushu Railway Company (JR Kyushu), a Japanese bullet train operator, is using the AMD Kria™ K26 System-on-Module (SOM) to automate track inspection. This AI-based solution replaces traditional methods of inspecting miles of track on foot, creating significant efficiencies by improving the inspection speed, cost and accuracy to meet Japan’s stringent railway safety requirements.

Key Points:

SANTA CLARA, Calif., Feb. 13, 2024 (GLOBE NEWSWIRE) -- AMD (NASDAQ: AMD) today announced that JR Kyushu Railway Company (JR Kyushu), a Japanese bullet train operator, is using the AMD Kria™ K26 System-on-Module (SOM) to automate track inspection.
JR Kyushu bullet trains operate across an enormous territory of more than 1,455 miles of railroad tracks, with trains traveling at speeds of up to 161 mph.
“With the new solution from TAI and AMD, we were able to improve the efficiency of conventional track inspection, and we anticipate further improvements in inspection efficiency through future functional enhancements,” said Kazuhiro Sakaguchi, deputy manager in the Engineering Division, Shinkansen Department at JR Kyushu.
At the heart of the track inspection solution is a vision computing box attached to a cart that inspects tracks at speeds of 12 mph.

Artios Pharma Strengthens Financial Leadership with Appointment of Christine Silverstein as Chief Financial Officer

Retrieved on:

Wednesday, February 7, 2024

Principal, Growth, CFO, ATR, Harvard University, DNA, FINRA, IPO, Drug discovery, Biotechnology, Drug development, Cancer, DNA repair, DDR, Business, Management

CAMBRIDGE, United Kingdom and NEW YORK, Feb. 07, 2024 (GLOBE NEWSWIRE) -- Artios Pharma Limited (“Artios”), clinical-stage biotech company led by pioneers of DNA damage response (“DDR”) drug development, announces the appointment of Christine Silverstein as Chief Financial Officer (CFO).

Key Points:

CAMBRIDGE, United Kingdom and NEW YORK, Feb. 07, 2024 (GLOBE NEWSWIRE) -- Artios Pharma Limited (“Artios”), clinical-stage biotech company led by pioneers of DNA damage response (“DDR”) drug development, announces the appointment of Christine Silverstein as Chief Financial Officer (CFO).
Niall Martin, Chief Executive Officer of Artios, said: “Christine is a seasoned CFO with robust capital markets expertise and a deep understanding of the industry landscape.
Christine Silverstein, Chief Financial Officer of Artios, added: “As recognized innovators in DDR drug discovery, Artios’ advanced pipeline targeting the DNA damage response offers cutting-edge approaches for difficult-to-treat cancers.
During her time at Abeona Therapeutics, Silverstein operated in multiple senior executive roles including CFO and Principal Financial Officer.

Varonis Introduces MDDR: Industry’s First Managed Data Detection and Response Offering

Retrieved on:

Monday, February 5, 2024

Cloud, MDDR, Varonis Systems, Automation, Running, DDR, MDR, Incident, SLA, Risk management

NEW YORK, Feb. 05, 2024 (GLOBE NEWSWIRE) -- Varonis Systems, Inc. (Nasdaq: VRNS), a leader in data security, today introduced Varonis Managed Data Detection and Response (MDDR), the industry’s first managed service dedicated to stopping threats at the data level.

Key Points:

NEW YORK, Feb. 05, 2024 (GLOBE NEWSWIRE) -- Varonis Systems, Inc. (Nasdaq: VRNS), a leader in data security, today introduced Varonis Managed Data Detection and Response (MDDR), the industry’s first managed service dedicated to stopping threats at the data level.
The offering combines Varonis’ award-winning threat detection technology and automation with a global team of elite threat hunters, forensics analysts, and incident responders who investigate and respond to threats 24x7x365.
“Organizations pay millions of dollars for threat detection products and services, yet when an incident occurs, they struggle to answer the most important question, ‘Was any data stolen?’” said Matt Radolec, Varonis VP of Incident Response and Cloud Operations.
“Varonis brings threat detection and response closer to the target — closer to the data.

Q4 UK Mortgage Arrears Climb Higher

Retrieved on:

Wednesday, January 31, 2024

Commercial Building & Real Estate, Construction & Property, Finance, Banking, Professional Services, Urban Planning, Fintech, Residential Building & Real Estate, ONS, Direct debit, Growth, DDR, Pressure, Ageing

Google Trends data shows that searches for “Can’t afford mortgage” increased 200% in 2023 compared to 2021, with a notable uptick in December 2023.

Key Points:

Google Trends data shows that searches for “Can’t afford mortgage” increased 200% in 2023 compared to 2021, with a notable uptick in December 2023.
Breaking down the arrears rate by product type, region and age reveals groups that are under particular stress:
Residential mortgage arrears grew 5.6% compared to Q3 and 29.0% year-on-year.
Regionally, the North East, Yorkshire and Humberside, the North West, and the West Midlands had the highest absolute rate of arrears in the UK.
Every age group experienced growth in the arrears rate that ranged from 0.3 to 0.8 percentage points quarter-on-quarter.

Introspect Technology Launches Protocol Analyzer to Accelerate Validating and Debugging of LPDDR5 and LPDDR5x Memory Interfaces

Retrieved on:

Wednesday, January 31, 2024

Memory, DDR5, LPDDR, Pop, BERT, CPU, DUT, Introspection, Packaging and labeling, LPDDR5, DDR

SANTA CLARA, Calif., Jan. 31, 2024 /PRNewswire-PRWeb/ -- Introspect Technology, a leading manufacturer of electronic test and measurement instruments for high-speed digital applications, proudly unveils the SV7M-LPDDR5PA Protocol Analyzer, a significant solution to advance validating and debugging of LPDDR5 and LPDDR5x memory interfaces. This release provides a complete toolkit performing true system level protocol analysis of DDR memory traffic, a radical departure from current industry convention.

Key Points:

SANTA CLARA, Calif., Jan. 31, 2024 /PRNewswire-PRWeb/ -- Introspect Technology, a leading manufacturer of electronic test and measurement instruments for high-speed digital applications, proudly unveils the SV7M-LPDDR5PA Protocol Analyzer , a significant solution to advance validating and debugging of LPDDR5 and LPDDR5x memory interfaces.
This release provides a complete toolkit performing true system level protocol analysis of DDR memory traffic, a radical departure from current industry convention.
"Built around the device under test (DUT) and deploying active probe technology, this protocol analyzer prioritizes in-place testing.
Visit Introspect Technology at DesignCon from January 31-February 1, 2024, at booth #960 for a live demo or, send an email to [email protected] .

Genialis and Debiopharm Set Up Biomarker Discovery Collaboration

Retrieved on:

Thursday, January 25, 2024

The initial phase kicked off this month, deploying Genialis’ biology-first, machine learning-enabled ResponderID framework to develop predictive biomarkers for DDR-directed therapies.

Key Points:

The initial phase kicked off this month, deploying Genialis’ biology-first, machine learning-enabled ResponderID framework to develop predictive biomarkers for DDR-directed therapies.
“Debiopharm continues to lead the oncology field in adopting artificial intelligence solutions at various stages across our preclinical and clinical development programs.
“Genialis’ RNA biomarkers have proved especially well-suited to support the development of new drugs targeting complex biological systems,” said Mark Uhlik, Vice President of Biomarker Discovery at Genialis.
Debiopharm is headquartered in Lausanne, Switzerland, and will be presenting at the 7th Annual DDR Inhibition Conference in Boston from January 29-30, 2024.

Genialis and Debiopharm Set Up Biomarker Discovery Collaboration

Retrieved on:

Thursday, January 25, 2024

The initial phase kicked off this month, deploying Genialis’ biology-first, machine learning-enabled ResponderIDTM framework to develop predictive biomarkers for DDR-directed therapies.

Key Points:

The initial phase kicked off this month, deploying Genialis’ biology-first, machine learning-enabled ResponderIDTM framework to develop predictive biomarkers for DDR-directed therapies.
“Debiopharm continues to lead the oncology field in adopting artificial intelligence solutions at various stages across our preclinical and clinical development programs.
“Genialis’ RNA biomarkers have proved especially well-suited to support the development of new drugs targeting complex biological systems,” said Mark Uhlik, Vice President of Biomarker Discovery at Genialis.
Debiopharm is headquartered in Lausanne, Switzerland, and will be presenting at the 7th Annual DDR Inhibition Conference in Boston from January 29-30, 2024.